Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients (AMBLED)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This will be a double-blind, randomised, placebo-controlled parallel-arm phase II proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing both end-of-dose wearing off and Levodopa-Induced Dyskinesia (LID)
A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)
Actual Study Start Date
July 4, 2017
Estimated Primary Completion Date
December 15, 2018
Estimated Study Completion Date
December 31, 2018
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
35 Years to 85 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males or females diagnosed after the age of 30 years with idiopathic PD for at least 3 years
Disease severity of 2 to 4 on the modified Hoehn and Yahr scale when in the OFF state
Been treated with a stable regimen of levodopa-containing therapy
Subjects who are on a long-acting formulation of levodopa-containing therapy, including Apodespan PR (or equivalent), must be on a stable dose for at least 6 weeks prior to the first screening visit
Experienced motor fluctuations with wearing off over a period of at least 3 months prior to randomisation
Experienced LID over a period of at least 3 months prior to randomisation
Female subjects will be women of non-childbearing potential
Subjects must pass a Hauser diary concordance test
Subjects are able, with or without the help of a caregiver, to understand the purpose and risks of the study and provide signed and dated informed consent and authorisation to use confidential health information in accordance with national and local subject privacy regulations
Subjects with atypical, secondary or drug-induced Parkinsonism
Subjects with a Mini-Mental State Examination (MMSE) score <25
Any known contraindication to the use of levodopa, including a history of malignant melanoma or a history of narrow-angle glaucoma.
Subjects who have had a clinically significant illness within 4 weeks of first dose, as determined by the Investigator.
Any advanced, severe or unstable disease (other than PD) that may interfere with the primary and secondary study outcome evaluations
Subjects who have undergone prior neurosurgical operation for PD or transcranial magnetic stimulation.
Subjects who are participating in another clinical study (eg, attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to the baseline visit.
Female subjects of childbearing potential
Subjects who are pregnant (as determined by positive serum pregnancy test at screening and/or baseline), breastfeeding or lactating.
Subjects who, in the opinion of the Investigator, should not participate in this study.